Ambrx Biopharma American Executives

AMAMDelisted Stock  USD 15.73  0.71  4.73%   
Ambrx Biopharma employs about 87 people. The company is managed by 18 executives with a total tenure of roughly 38 years, averaging almost 2.0 years of service per executive, having 4.83 employees per reported executive. Analysis of Ambrx Biopharma's management performance can provide insight into the firm performance.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Ambrx Biopharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.1862) % which means that it has lost $0.1862 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3723) %, meaning that it created substantial loss on money invested by shareholders. Ambrx Biopharma's management efficiency ratios could be used to measure how well Ambrx Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.

Ambrx Biopharma Workforce Comparison

Ambrx Biopharma American is rated third in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 656. Ambrx Biopharma retains roughly 87.0 in number of employees claiming about 13% of equities under Health Care industry.

Ambrx Biopharma Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ambrx Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ambrx Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Ambrx Biopharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Ambrx Biopharma Notable Stakeholders

An Ambrx Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ambrx Biopharma often face trade-offs trying to please all of them. Ambrx Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ambrx Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Daniel JDPresident CEOProfile
Feng TianChairman of the Board, President, Chief Executive OfficerProfile
Sonja NelsonChief Financial OfficerProfile
Jared KellyGeneral VPProfile
Xiao LeDirectorProfile
Robert AzzaraVice CapitalProfile
Xiaowei ChangDirectorProfile
Katrin RupallaIndependent DirectorProfile
Joy YanChief Medical OfficerProfile
Shawn ZhangChief OfficerProfile
Olivia WareIndependent DirectorProfile
Ying BuechlerChief OfficerProfile
Sonja CPAChief OfficerProfile
Andrew AromandoChief OfficerProfile
Simon AllenChief Business OfficerProfile
Renu MScChief OfficerProfile
Chris NoletIndependent DirectorProfile
Sandra AungChief OfficerProfile

About Ambrx Biopharma Management Performance

The success or failure of an entity such as Ambrx Biopharma American often depends on how effective the management is. Ambrx Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ambrx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ambrx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. The company was incorporated in 2003 and is headquartered in La Jolla, California. Ambrx Biopharma operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 81 people.

Ambrx Biopharma Workforce Analysis

Traditionally, organizations such as Ambrx Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ambrx Biopharma within its industry.

Ambrx Biopharma Manpower Efficiency

Return on Ambrx Biopharma Manpower

Revenue Per Employee47K
Revenue Per Executive227.4K
Net Loss Per Employee770.8K
Net Loss Per Executive3.7M
Working Capital Per Employee849.7K
Working Capital Per Executive4.1M
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Other Consideration for investing in Ambrx Stock

If you are still planning to invest in Ambrx Biopharma American check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ambrx Biopharma's history and understand the potential risks before investing.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency